TMIC-15. Reactive Oligodendrocytes Promote Glioblastoma Progression via CCL5/CCR5-Mediated Glioma Stem Cell Maintenance

Abstract BACKGROUND Glioblastoma (GBM) progression is tightly linked to microenvironmental interactions that remain poorly defined. Oligodendrocyte-lineage cells (OLs), traditionally viewed as passive bystanders, are increasingly recognized in the GBM niche, yet their functional role remains unexplored. METHODS Using integrated single-cell RNA sequencing, spatial transcriptomics, cytokine profiling, and functional assays across primary (newly diagnosed) and recurrent GBM samples, we investigated OL-GBM interactions. An OL meta-atlas encompassing 336,000 OL cells from 226 patients was constructed to contextualize OL phenotypes across CNS pathologies. RESULTS We found OLs are selectively recruited to the GBM tumor border via tumor-secreted CX3CL1 and infiltrate the tumor core at recurrence. Tumor-associated OLs adopt an interferon-driven reactive state, distinct from their healthy counterparts. These reactive OLs secrete pro-tumorigenic cytokines, including CCL5. We show that CCL5 supports GBM cell proliferation, particularly in recurrent GBM. Its receptor, CCR5, was selectively expressed in glioma stem-like cells (GSCs) and correlated with poor prognosis. Genetic and pharmacologic CCR5 inhibition impaired GSC viability, reduced tumor burden, and extended survival in orthotopic xenografts. CONCLUSIONS Our study identifies a previously unrecognized paracrine axis between reactive OLs and GSCs mediated by CCL5/CCR5 signalling. This axis is amplified in recurrence and represents a therapeutic vulnerability in GBM. Targeting microenvironmental contributors such as OLs may complement existing GBM therapies.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-11-01
DOI
https://doi.org/10.1093/neuonc/noaf201.1770
Citations
1
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
1.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

TMIC-15. Reactive Oligodendrocytes Promote Glioblastoma Progression via CCL5/CCR5-Mediated Glioma Stem Cell Maintenance

Chitra Venugopal, Sheila Kumari Singh, Nicholas Mikolajewicz, Kui Zhai et al.
1 citations
Neuro-Oncology
Glioma Diagnosis and Treatment
1.63
article

TMIC-15. Reactive Oligodendrocytes Promote Glioblastoma Progression via CCL5/CCR5-Mediated Glioma Stem Cell Maintenance

Chitra Venugopal, Sheila Kumari Singh, Nicholas Mikolajewicz, Kui Zhai, Jason Moffat
article en
1 citations

Abstract

Abstract BACKGROUND Glioblastoma (GBM) progression is tightly linked to microenvironmental interactions that remain poorly defined. Oligodendrocyte-lineage cells (OLs), traditionally viewed as passive bystanders, are increasingly recognized in the GBM niche, yet their functional role remains unexplored. METHODS Using integrated single-cell RNA sequencing, spatial transcriptomics, cytokine profiling, and functional assays across primary (newly diagnosed) and recurrent GBM samples, we investigated OL-GBM interactions. An OL meta-atlas encompassing 336,000 OL cells from 226 patients was constructed to contextualize OL phenotypes across CNS pathologies. RESULTS We found OLs are selectively recruited to the GBM tumor border via tumor-secreted CX3CL1 and infiltrate the tumor core at recurrence. Tumor-associated OLs adopt an interferon-driven reactive state, distinct from their healthy counterparts. These reactive OLs secrete pro-tumorigenic cytokines, including CCL5. We show that CCL5 supports GBM cell proliferation, particularly in recurrent GBM. Its receptor, CCR5, was selectively expressed in glioma stem-like cells (GSCs) and correlated with poor prognosis. Genetic and pharmacologic CCR5 inhibition impaired GSC viability, reduced tumor burden, and extended survival in orthotopic xenografts. CONCLUSIONS Our study identifies a previously unrecognized paracrine axis between reactive OLs and GSCs mediated by CCL5/CCR5 signalling. This axis is amplified in recurrence and represents a therapeutic vulnerability in GBM. Targeting microenvironmental contributors such as OLs may complement existing GBM therapies.

Neuro-OncologyVol. 27(Supplement_5)
University of Toronto (CA), Hospital for Sick Children (CA), McMaster University (CA)
Openalex Percentile: Top 12%
Glioma Diagnosis and Treatment
1.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.